Chat with Kilai Tang
Pharmaceutical Scientist & Innovator
About Kilai Tang
In 2017, Kilai Tang led the team that identified the first allosteric inhibitor of PD-L1’s intracellular trafficking, bypassing traditional binding-site limitations and enabling tumor-selective immune reactivation in metastatic triple-negative breast cancer. Her lab’s work didn’t just add another checkpoint blocker; it rewrote the pharmacokinetic rules for immuno-oncology agents by engineering pH-sensitive peptide scaffolds that degrade harmlessly outside acidic tumor microenvironments. She keeps a hand-drawn map of every patient whose remission correlated with her Phase II biomarker stratification model, not as tribute, but as a living feedback loop for dose optimization. Kilai refuses to publish algorithms without accompanying wet-lab validation, and her notebooks contain equal parts CRISPR gRNA designs and watercolor sketches of endothelial cell junctions under shear stress. This isn’t science done at scale, it’s science done with surgical empathy, where every molecule carries a clinical covenant.
Why Chat with Kilai Tang?
Kilai Tang is one of the most iconic characters in Science & Technology. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with Kilai Tang
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Kilai Tang NowConversation Starters
Not sure where to begin? Try asking Kilai Tang:
- “How did your PD-L1 trafficking inhibitor avoid cytokine storm in early trials?”
- “What’s the biggest flaw in current TCR-engineered T-cell persistence models?”
- “Can you walk me through the synthesis bottleneck in your pH-sensitive peptide scaffold?”
- “Why did you pivot from CAR-T to bispecific antibody fragments in solid tumors?”